7th ICHNO Abstract book

page 72 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ 7th ICHNO

treatment. Pearson’s test was used to assess the correlation between mean laryngeal dose and laryngeal edema and laryngeal edema and tumor site. Wilcoxon’s sign rank test was used to compare the difference in the MPT, GRBAS scores, F 0 variations in vowels and in speech pre and post treatment at 3 and 6 months. Results In the study population, Median age was 59 years and 88% of patients were males. 80% of the patients were smokers and 72 % were alcoholics. The site wise distribution of tumors is as follows: 40% oropharynx, 12%hypopharynx, & 48 %larynx. 78% patients were locally advanced SCC. 56% of the tumors were well differentiated. 14 out of 25 patients received concurrent chemotherapy. Median duration of the treatment was 51 days. The mean laryngeal dose was 62.4 Gy ±6.2 Gy. At baseline the number of patients with mild and moderate laryngeal edema was 9 and 1 which increased to 18 and 4 at 3 months and 10 and 13 at 6 months respectively. The incidence of laryngeal edema at 6 months correlated with the Mean laryngeal dose ( p <0.001) and site of tumor ( p =0.04). Perceptual assessment of voice by GRBAS showed a trend of improvement at 3 months with the difference in the breathiness component attaining significance ( p =0.04) and a worsening at 6 months post RT with change in strain component of the voice being significant ( p =0.02). The MPT showed an improvement from the baseline at 3 months post RT but this improvement was not seen at 6 months. A possible explanation could be due to the increased occurrence of laryngeal edema 6 months post RT. The F 0 for the vowels a, i, u and the Mean Spoken Fundamental Frequency decreased from the baseline at 3 months and 6 months post RT but the decrease was not statistically significant. Conclusion Laryngeal edema at 6 months correlated with the Mean laryngeal dose and site of tumor. Perceptual assessment by GRBAS showed significant change in the breathiness and strain at 3 and 6 months respectively. PO-136 Haed and Neck symptoms evolution during chemo-radiotherapy: A prospective assessment N. Fourati 1 , Z. Fessi 1 , W. Mnejja 1 , O. Nouri 1 , W. Ben Kridis 2 , A. Khanfir 2 , W. Siala 1 , J. Daoud 1 1 Hopital Habib Bourguiba, Radiation Oncology, Sfax, Tunisia; 2 Hopital Habib Bourguiba, Medical Oncology, Sfax, Tunisia Purpose or Objective Head and neck (HN) symptoms are responsible for a deterioration of patients' quality of life (QOL) during concurrent chemo-radiotherapy (CCR) for nasopharyngeal carcinomas (NPC). Several rating scales are available to assess the importance of the symptoms and the QOL of cancer patients. The aim of our study was to evaluate the evolution of HN symptoms during the CCR through the EORTC QOL HN35 quality of life questionnaire. Difference in F 0 from baseline at 3 months[Hz] Difference in F 0 from baseline at 6 months[Hz] Vowel a Vowel i Vowel u -17 -21 -8 -15 -12.8 -6.5 Mean Spoken Fundamental Frequency -6.3 -12.7

Material and Methods A prospective study of 25 patients treated with CCR for NPC between October 2017 and July 2018. Median age was 46 years [26-72] with a sex ratio of 2.1. The majority of patients (92%) received first-line chemotherapy. All patients received intensity modulated radiotherapy at a dose of 70 Gy with weekly cisplatin (40mg/m²) chemotherapy. During the treatment period, patients completed the EORTC QLQ C30 and HN35 QOL (adapted for Tunisia) questionnaires weekly. In this study we had only evaluate the following symptoms: pain (PA), swallowing (SW), senses problems (SE), speech problems (SP), trouble with social eating (SO), trouble with social contact(SC), teeth (TE), opening mouth (OM), dry mouth (DR), sticky saliva (SS), coughing (CO) and felt ill (FI). A high score for a symptom represents a high level of symptomatology. Xilcoxon Test was used to compare mean scores : between the first Day (FD) and the last day (LD) of treatment. Results The Means of percentages for each symptom are summarized in Table 1. The difference between the FD and the LD symptoms were all statistically significant except for TE.

Mean at FD (%) Mean at LD (%) p

PA 7.7

61 59

<0.001 <0.001 <0.001 <0.001 <0.001

SW 7

SE 9.3 SP 4.9

54.6 32.4

SO 4

54

SC 4.8

30.7 22.7

0.001

TE 16

0.44

OM 5.3 DM 29.3 SS 21.3

44 68

0.001 0.004 0.001

66.6 47.1 57.3

CO 8

<0.001 <0.001

FI 18.7

Conclusion Quality of life is an important treatment outcome in NPC. In the literature, QOL assessment is generally lacking and is often relevant to late toxicities only. However, as shown by the results of our study, the initial phase of treatment is also responsible for a significant deterioration in the QOL of patients that must be considered. PO-137 Psycho-Social Issues in Ca Head and Neck survivors with respect to physical wellbeing- A retrospective study A. Tiwari 1 1 Royal Cancer Hospital and Research Institute, Radiation Oncology, Kanpur, India Purpose or Objective Patients with head and neck cancer (HNC) face potentially life-threatening diagnosis and need to endure treatment that often results in significant, highly visible disfigurement and disruptions of essential bodily functions. Common problems are issues related to eating, swallowing, breathing, and speech as well as pain. Disturbances in psycho-social functioning and psychological distress are reported by a considerable number of patients; worry, anxiety, mood disorder, fatigue, and depression are the main symptoms. Cancer of